NRX Pharmaceuticals
NRXP· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock -52.2% in FY2024
Jonathan Javitt is the CEO of NRX Pharmaceuticals and was paid $825.0K in FY2024 (Dec), up 31%.
Pay$100 in the stock at the end of FY22 → $20
Executives5
See all- 1Jonathan JavittChief Executive Officer, Chief Scientist and ChairmanFY2024
- 2Richard NaridoFormer Chief Financial OfficerFY2024
- 3Stephen WillardFormer Chief Executive OfficerFY2024
- 4Matthew DuffyChief Business OfficerFY2024
- 5Michael AbramsChief Financial OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allNRX Pharmaceuticals paid its 5 named executives $2.0M in total in FY2024 (Dec). CEO Jonathan Javitt was paid $825.0K of that.
| Name | ||
|---|---|---|
| Jonathan JavittChief Executive Officer, Chief Scientist and Chairman | ||
| Richard NaridoFormer Chief Financial Officer | ||
| Stephen WillardFormer Chief Executive Officer | ||
| Matthew DuffyChief Business Officer | ||
| Michael AbramsChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for NRX Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings5
See all| Annual report | 10-K | Mar 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | Feb 23, 2026 | FY2024 |
| Annual report | 10-K | Mar 14, 2025 | FY2024 |
| Annual report | 10-K | Mar 29, 2024 | FY2023 |
| Proxy statement | DEF 14A | Mar 11, 2024 | — |
